[go: up one dir, main page]

ES8304797A1 - "procedimiento para la preparacion de nuevas formas orales de dipiridamol, en forma de granulados, pastillas o tabletas". - Google Patents

"procedimiento para la preparacion de nuevas formas orales de dipiridamol, en forma de granulados, pastillas o tabletas".

Info

Publication number
ES8304797A1
ES8304797A1 ES513235A ES513235A ES8304797A1 ES 8304797 A1 ES8304797 A1 ES 8304797A1 ES 513235 A ES513235 A ES 513235A ES 513235 A ES513235 A ES 513235A ES 8304797 A1 ES8304797 A1 ES 8304797A1
Authority
ES
Spain
Prior art keywords
acid
dipyridamole
host
addition salt
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES513235A
Other languages
English (en)
Other versions
ES513235A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Dr Karl Thomae GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6134913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8304797(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dr Karl Thomae GmbH filed Critical Dr Karl Thomae GmbH
Publication of ES8304797A1 publication Critical patent/ES8304797A1/es
Publication of ES513235A0 publication Critical patent/ES513235A0/es
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROCEDIMIENTO PARA LA PREPARACION DE FORMAS ORALES DE DIPIRIDAMOL, EN FORMA DE GRANULADOS, PASTILLAS O TABLETAS. CONSISTE EN MEZCLAR UN MOLDE DE DIPIRIDAMOL O UN MOL DE SU SAL POR ADICION DE ACIDOS CON, AL MENOS, CINCO MOLES EQUIVALENTES DE UNA SUSTANCIA AUXILIAR ACIDA, TOLERABLE POR VIA ORAL, Y EVENTUALMENTE ADEMAS CON ADITIVOS HABITUALES, PARA FORMAR GRANULOS O GRANULADOS. DICHOS GRANULOS O GRANULADOS OBTENIDOS SEGUN EL PROCEDIMIENTO INDICADO SE COMPRIMEN PARA FORMAR TABLETAS. COMO SUSTANCIAS ACIDAS SE EMPLEAN ACIDO TARTARICO, ACIDO CITRICO, ACIDO FUMARICO, ACIDO SUCCINICO, ACIDO MALICO Y SIMILARES.
ES513235A 1981-06-19 1982-06-18 "procedimiento para la preparacion de nuevas formas orales de dipiridamol, en forma de granulados, pastillas o tabletas". Granted ES513235A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19813124090 DE3124090A1 (de) 1981-06-19 1981-06-19 Neue orale dipyridamolformen

Publications (2)

Publication Number Publication Date
ES8304797A1 true ES8304797A1 (es) 1983-03-16
ES513235A0 ES513235A0 (es) 1983-03-16

Family

ID=6134913

Family Applications (1)

Application Number Title Priority Date Filing Date
ES513235A Granted ES513235A0 (es) 1981-06-19 1982-06-18 "procedimiento para la preparacion de nuevas formas orales de dipiridamol, en forma de granulados, pastillas o tabletas".

Country Status (27)

Country Link
US (1) US4427648A (es)
EP (1) EP0068191B2 (es)
JP (1) JPS5849312A (es)
KR (1) KR880001090B1 (es)
AR (1) AR228779A1 (es)
AT (1) ATE17317T1 (es)
AU (1) AU555951B2 (es)
CA (1) CA1200496A (es)
DD (1) DD202505A5 (es)
DE (2) DE3124090A1 (es)
DK (1) DK158540C (es)
ES (1) ES513235A0 (es)
FI (1) FI80829C (es)
GB (1) GB2101484B (es)
GR (1) GR76503B (es)
HU (1) HU186078B (es)
IE (1) IE53543B1 (es)
IL (1) IL66075A (es)
IN (1) IN158513B (es)
MA (1) MA19503A1 (es)
MX (1) MX160712A (es)
MY (1) MY8700727A (es)
NZ (1) NZ201008A (es)
PH (1) PH25637A (es)
PT (1) PT75077B (es)
SU (1) SU1151193A3 (es)
ZA (1) ZA824315B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
KR880002139B1 (ko) * 1983-04-08 1988-10-17 베링거 인겔하임 리미티드 경구 투여용 정제의 제조방법
DE3314003A1 (de) * 1983-04-18 1984-10-18 Boehringer Ingelheim KG, 6507 Ingelheim Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung
DE3320582A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method
GB8813032D0 (en) * 1988-06-02 1988-07-06 Boehringer Ingelheim Int Antiviral pharmaceutical composition
US5064656A (en) * 1989-11-14 1991-11-12 Dr. Gergely & Co. Uncoated pharmaceutical reaction tablet
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
US5364646A (en) * 1990-01-10 1994-11-15 Dr. Karl Thomae Gmbh Oral pharmaceutical forms of pimobendan
HU222489B1 (hu) * 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
US6300361B1 (en) 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
AU2016992A (en) * 1991-05-20 1992-12-30 Marion Laboratories, Inc. Multi-layered controlled release formulation
US5302393A (en) * 1991-07-11 1994-04-12 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Method for inhibiting biological degradation of implantation polymeric material, inhibitor thereof and implantation polymeric material containing the inhibitor
US5270047A (en) * 1991-11-21 1993-12-14 Kauffman Raymond F Local delivery of dipyridamole for the treatment of proliferative diseases
DE19845358A1 (de) 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
JP4331930B2 (ja) * 2001-10-17 2009-09-16 武田薬品工業株式会社 酸に不安定な薬物の高含量顆粒
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
EP1594503A2 (en) * 2003-02-07 2005-11-16 Boehringer Ingelheim International GmbH Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders
DE10306179A1 (de) 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
KR20060007034A (ko) 2003-04-24 2006-01-23 베링거 인겔하임 인터내셔날 게엠베하 혈전색전증 질환 및 트롬빈의 과형성 및/또는 트롬빈수용체의 상승된 발현에 의해 유발된 질환 및 장애를치료하고 예방하기 위한, 디피리다몰 또는 모피다몰의 용도
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
CA2566081A1 (en) * 2004-05-13 2005-12-01 Boehringer Ingelheim International Gmbh Use of dipyridamole for treatment of resistance to platelet inhibitors
BG860Y1 (bg) * 2004-09-17 2007-02-28 "Софарма" Ад Лекарствена форма на дипиридамол
EP1863460B1 (en) 2005-03-22 2013-01-16 Losan Pharma GmbH Solubilized ibuprofen
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
GB0517204D0 (en) * 2005-08-22 2005-09-28 Novartis Ag Organic compounds
AU2006284053B2 (en) * 2005-08-22 2010-04-22 Novartis Ag Pharmaceutical compositions comprising a pH-dependent drug, a pH modifier and a retarding agent
CN101410094B (zh) * 2006-01-27 2013-04-17 阿普塔利斯制药股份有限公司 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
KR101489401B1 (ko) * 2006-01-27 2015-02-03 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
AU2006337643A1 (en) * 2006-02-09 2007-08-16 Teva Pharmaceutical Industries Ltd. Dipyridamole extended-release formulations and process for preparing same
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
JP5783725B2 (ja) 2007-12-28 2015-09-24 インパックス ラボラトリーズ、 インコーポレイテッドＩｍｐａｘ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． レボドパの放出制御製剤及びその使用
US20090196935A1 (en) * 2008-02-01 2009-08-06 Ahmed Salah U Pharmaceutical Capsules Comprising Extended Release Dipyridamole Pellets
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
WO2010036975A2 (en) * 2008-09-25 2010-04-01 Teva Pharmaceutical Industries Ltd. Dipyridamole and acetylsalicylic acid formulations and process for preparing same
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US20110027771A1 (en) * 2009-07-31 2011-02-03 Artemis Health, Inc. Methods and compositions for cell stabilization
EP2361615A1 (en) 2010-02-19 2011-08-31 Alfred E. Tiefenbacher GmbH & Co. KG Dipyridamole prolonged-release tablet
WO2012162492A1 (en) * 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Compressed core comprising organic acids for a pharmaceutical composition
ES2924478T3 (es) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos
CN105377235A (zh) 2013-07-19 2016-03-02 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
EP3782614A1 (en) 2013-10-07 2021-02-24 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
KR102308973B1 (ko) 2013-12-04 2021-10-08 베링거잉겔하임베트메디카게엠베하 개선된 피모벤단의 약제학적 조성물
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
WO2022140448A1 (en) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2157201C3 (de) * 1970-11-13 1974-12-12 Boehringer Mannheim Gmbh, 6800 Mannheim Verbesserte feste orale Applikationsform von Raubasin
DE2700433A1 (de) * 1977-01-07 1978-07-20 Kali Chemie Pharma Gmbh Arzneimittelzubereitungen mit verbesserten resorptionseigenschaften
LU77353A1 (es) * 1977-05-16 1979-01-19
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
IE48715B1 (en) * 1978-12-22 1985-05-01 Elan Corp Plc New galencial forms for administration of medicaments by oral route,with programmed release and processes for preparing same
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
JPS6116368A (ja) * 1984-07-02 1986-01-24 Mitsubishi Electric Corp 画像処理装置の検査装置

Also Published As

Publication number Publication date
GR76503B (es) 1984-08-10
IE821453L (en) 1982-12-19
MX160712A (es) 1990-04-23
KR840000229A (ko) 1984-02-18
AR228779A1 (es) 1983-04-15
EP0068191B1 (de) 1986-01-08
SU1151193A3 (ru) 1985-04-15
IN158513B (es) 1986-11-29
CA1200496A (en) 1986-02-11
EP0068191B2 (de) 1991-09-11
ZA824315B (en) 1984-02-29
EP0068191A3 (en) 1983-08-10
EP0068191A2 (de) 1983-01-05
AU555951B2 (en) 1986-10-16
PH25637A (en) 1991-08-21
DE3268380D1 (en) 1986-02-20
DK269682A (da) 1982-12-20
IL66075A (en) 1985-09-29
IE53543B1 (en) 1988-12-07
GB2101484B (en) 1984-09-19
FI80829B (fi) 1990-04-30
DK158540B (da) 1990-06-05
DE3124090A1 (de) 1983-01-05
ES513235A0 (es) 1983-03-16
GB2101484A (en) 1983-01-19
AU8496582A (en) 1982-12-23
ATE17317T1 (de) 1986-01-15
US4427648A (en) 1984-01-24
DE3124090C2 (es) 1991-11-21
FI822173A0 (fi) 1982-06-17
JPH0251402B2 (es) 1990-11-07
NZ201008A (en) 1985-11-08
FI80829C (fi) 1990-08-10
PT75077B (de) 1985-05-31
PT75077A (de) 1982-07-01
FI822173L (fi) 1982-12-20
DD202505A5 (de) 1983-09-21
KR880001090B1 (ko) 1988-06-23
MA19503A1 (fr) 1982-12-31
JPS5849312A (ja) 1983-03-23
DK158540C (da) 1990-11-12
HU186078B (en) 1985-05-28
MY8700727A (en) 1987-12-31
IL66075A0 (en) 1982-09-30

Similar Documents

Publication Publication Date Title
ES8304797A1 (es) "procedimiento para la preparacion de nuevas formas orales de dipiridamol, en forma de granulados, pastillas o tabletas".
ES8500743A1 (es) Procedimiento para preparar formas de mopidamol como granulados, granulos o tabletas
MX9605650A (es) Formulaciones de propionato de fluticasona.
UA27760C2 (uk) Композиція у вигляді наночасток і спосіб її одержання
MX9504034A (es) Formas de administracion medicamentosas que contienen acido tioctico, o sales solidas del acido tioctico de liberacion y biodisponibilidad mejoradas.
SE9701956D0 (sv) New composition of matter
AU4515985A (en) New tetrapyrrole therapeutic agents
EP0660705A4 (en) ADVANCED DRUG DELIVERY SYSTEM AND METHOD FOR TREATING PSYCHIATRIC, NEUROLOGICAL AND OTHER DISEASES WITH CARBAMAZEPINE.
DE69320646D1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
CA2150184A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel diseases
DE19975006I2 (de) Pharmazeutische Zusammensetzungen zur Behandlung gastrointestinaler St¦rungen.
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
EP0911331A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
EP0169392A3 (en) Triazolobenzodiazepines and pharmaceutical compositions containing them
CA2132544A1 (en) Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
FR2500303B1 (es)
NZ296765A (en) 8-cyclohexyl substituted xanthine derivatives and medicaments
DK484585D0 (da) Micellulaere partikelkompositioner, hvori er indkapslet billedtagende og kemoterapeutiske midler for tumorer, og kompositionernes anvendelse
DE3380923D1 (de) Pharmazeutische zusammensetzungen zur behandlung von stoerungen, bedingt durch humanendrogen.
WO1994013304A3 (en) Antacid composition and method of production
EP0790250A3 (en) Inhibitors of biogenic amine transporters
EP0348664A3 (en) Pharmaceutical compositions containing monoacetoacetins for treating tumours
DE69736955D1 (de) Verfahren und zusammensetzungen zur vorbeugung und behandlung von sodbrennen
PL320996A1 (en) 4,4-(disubstituted) monomers of cyclohexan-1-ol and compounds shoving affinity to them
MX9602846A (es) Compuestos de vanadato para el tratamiento de desordenes proliferativos, metastasis, y tumores resistentes a los farmacos.